Open AccessLow Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders
Author(s) -
Andrea Calcagno,
Ivano Dal Conte,
Dario Cattaneo,
Roberto Testi,
Massimiliano Mistrangelo,
Cristina Gervasoni,
Amedeo De Nicolò,
Stefano Bonora,
Antonio D’Avolio,
Giovanni Di Perri
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01902-20
Subject(s) - medicine , tenofovir , emtricitabine , pre exposure prophylaxis , gastroenterology , diarrhea , gastrointestinal disease , human immunodeficiency virus (hiv) , disease , viral load , antiretroviral therapy , immunology , men who have sex with men , syphilis
Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.